These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38958200)

  • 1. Backbone-Determined Antiarrhythmic Structure-Activity Relationships for a Mirror Image, Oligomeric Depsipeptide Natural Product.
    Thorpe MP; Blackwell DJ; Knollmann BC; Johnston JN
    J Med Chem; 2024 Jul; ():. PubMed ID: 38958200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unnatural verticilide enantiomer inhibits type 2 ryanodine receptor-mediated calcium leak and is antiarrhythmic.
    Batiste SM; Blackwell DJ; Kim K; Kryshtal DO; Gomez-Hurtado N; Rebbeck RT; Cornea RL; Johnston JN; Knollmann BC
    Proc Natl Acad Sci U S A; 2019 Mar; 116(11):4810-4815. PubMed ID: 30792355
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Gochman A; Do TQ; Kim K; Schwarz JA; Thorpe MP; Blackwell DJ; Ritschel PA; Smith AN; Rebbeck RT; Akers WS; Cornea RL; Laver DR; Johnston JN; Knollmann BC
    Mol Pharmacol; 2024 Feb; 105(3):194-201. PubMed ID: 38253398
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Gochman A; Do TQ; Kim K; Schwarz JA; Thorpe MP; Blackwell DJ; Smith AN; Akers WS; Cornea RL; Laver DR; Johnston JN; Knollmann BC
    bioRxiv; 2023 Jul; ():. PubMed ID: 37461611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RyR2 Binding of an Antiarrhythmic Cyclic Depsipeptide Mapped Using Confocal Fluorescence Lifetime Detection of FRET.
    Šeflová J; Schwarz JA; Smith AN; Svensson B; Blackwell DJ; Phillips TA; Nikolaienko R; Bovo E; Rebbeck RT; Zima AV; Thomas DD; Van Petegem F; Knollmann BC; Johnston JN; Robia SL; Cornea RL
    ACS Chem Biol; 2023 Oct; 18(10):2290-2299. PubMed ID: 37769131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-Activity Relationships for the
    Smith AN; Thorpe MP; Blackwell DJ; Batiste SM; Hopkins CR; Schley ND; Knollmann BC; Johnston JN
    ACS Med Chem Lett; 2022 Nov; 13(11):1755-1762. PubMed ID: 36385927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Pharmacokinetic and Pharmacodynamic Properties of the Antiarrhythmic Molecule
    Blackwell DJ; Smith AN; Do T; Gochman A; Schmeckpeper J; Hopkins CR; Akers WS; Johnston JN; Knollmann BC
    J Pharmacol Exp Ther; 2023 Jun; 385(3):205-213. PubMed ID: 36894328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective RyR2 inhibitor ent-verticilide suppresses atrial fibrillation susceptibility caused by Pitx2 deficiency.
    Kim K; Blackwell DJ; Yuen SL; Thorpe MP; Johnston JN; Cornea RL; Knollmann BC
    J Mol Cell Cardiol; 2023 Jul; 180():1-9. PubMed ID: 37080450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verticilide: elucidation of absolute configuration and total synthesis.
    Monma S; Sunazuka T; Nagai K; Arai T; Shiomi K; Matsui R; Omura S
    Org Lett; 2006 Nov; 8(24):5601-4. PubMed ID: 17107082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verticilide, a new ryanodine-binding inhibitor, produced by Verticillium sp. FKI-1033.
    Shiomi K; Matsui R; Kakei A; Yamaguchi Y; Masuma R; Hatano H; Arai N; Isozaki M; Tanaka H; Kobayashi S; Turberg A; Omura S
    J Antibiot (Tokyo); 2010 Feb; 63(2):77-82. PubMed ID: 20057513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ring Size as an Independent Variable in Cyclooligomeric Depsipeptide Antiarrhythmic Activity.
    Smith AN; Blackwell DJ; Knollmann BC; Johnston JN
    ACS Med Chem Lett; 2021 Dec; 12(12):1942-1947. PubMed ID: 34917258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.
    Klipp RC; Li N; Wang Q; Word TA; Sibrian-Vazquez M; Strongin RM; Wehrens XHT; Abramson JJ
    Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
    Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
    Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.
    Kryshtal DO; Blackwell DJ; Egly CL; Smith AN; Batiste SM; Johnston JN; Laver DR; Knollmann BC
    Circ Res; 2021 Feb; 128(3):321-331. PubMed ID: 33297863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potent and selective cis-amide inhibitor of ryanodine receptor 2 as a candidate for cardiac arrhythmia treatment.
    Ishida R; Kurebayashi N; Iinuma H; Zeng X; Mori S; Kodama M; Murayama T; Masuno H; Takeda F; Kawahata M; Tanatani A; Miura A; Nishio H; Sakurai T; Kagechika H
    Eur J Med Chem; 2023 Dec; 262():115910. PubMed ID: 37922828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced Cytosolic Ca2+ Activation Underlies a Common Defect of Central Domain Cardiac Ryanodine Receptor Mutations Linked to Arrhythmias.
    Xiao Z; Guo W; Sun B; Hunt DJ; Wei J; Liu Y; Wang Y; Wang R; Jones PP; Back TG; Chen SRW
    J Biol Chem; 2016 Nov; 291(47):24528-24537. PubMed ID: 27733687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenytoin Reduces Activity of Cardiac Ryanodine Receptor 2; A Potential Mechanism for Its Cardioprotective Action.
    Ashna A; van Helden DF; Dos Remedios C; Molenaar P; Laver DR
    Mol Pharmacol; 2020 Apr; 97(4):250-258. PubMed ID: 32015008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The central domain of cardiac ryanodine receptor governs channel activation, regulation, and stability.
    Guo W; Sun B; Estillore JP; Wang R; Chen SRW
    J Biol Chem; 2020 Nov; 295(46):15622-15635. PubMed ID: 32878990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for Novel Type 2 Ryanodine Receptor Inhibitors by Endoplasmic Reticulum Ca
    Takenaka M; Kodama M; Murayama T; Ishigami-Yuasa M; Mori S; Ishida R; Suzuki J; Kanemaru K; Sugihara M; Iino M; Miura A; Nishio H; Morimoto S; Kagechika H; Sakurai T; Kurebayashi N
    Mol Pharmacol; 2023 Dec; 104(6):275-286. PubMed ID: 37678938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RyR2 disease mutations at the C-terminal domain intersubunit interface alter closed-state stability and channel activation.
    Guo W; Wei J; Estillore JP; Zhang L; Wang R; Sun B; Chen SRW
    J Biol Chem; 2021 Jul; 297(1):100808. PubMed ID: 34022226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.